Modern haemophilia care
- PMID: 22456059
- DOI: 10.1016/S0140-6736(11)61139-2
Modern haemophilia care
Abstract
Haemophilia care has undergone substantial improvements during the past 40-50 years. Early clotting factor concentrates were not sufficiently refined to enable self-administered treatment at home until the 1970s. Unfortunately, these advances led to transmission of viral diseases including HIV and hepatitis, resulting in an increased burden of morbidity and mortality, especially during the 1980s. Throughout the past two decades, product development, including the advent of recombinant concentrates, has greatly improved the safety and availability of therapy and the focus of care is shifting towards prevention and management of disease sequelae. Long-term substitution therapy (prophylaxis) of the missing clotting factor is the recommended treatment in severe haemophilia, but several research issues remain to be elucidated such as when to start and how to optimise these regimens, and when or whether to stop this expensive treatment. The major side-effect of treatment, development of inhibitors to the infused concentrate, is the main threat to the health of patients and consequently the goal of intense research. Development of new products with improved pharmacokinetics is the next step to improved therapy.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Rationale for individualizing haemophilia care.Blood Coagul Fibrinolysis. 2015 Dec;26(8):849-57. doi: 10.1097/MBC.0000000000000225. Blood Coagul Fibrinolysis. 2015. PMID: 25396764 Review.
-
Haemophilia care then, now and in the future.Haemophilia. 2009 Jan;15 Suppl 1:2-7. doi: 10.1111/j.1365-2516.2008.01946.x. Haemophilia. 2009. PMID: 19125934 Review.
-
Optimizing factor prophylaxis for the haemophilia population: where do we stand?Haemophilia. 2004 Oct;10 Suppl 4:97-104. doi: 10.1111/j.1365-2516.2004.00998.x. Haemophilia. 2004. PMID: 15479380 Review.
-
On-demand treatment in persons with severe haemophilia.Eur J Haematol Suppl. 2014 Aug;76:39-47. doi: 10.1111/ejh.12373. Eur J Haematol Suppl. 2014. PMID: 24957106 Review.
-
Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.Haemophilia. 2013 Jan;19(1):27-34. doi: 10.1111/j.1365-2516.2012.02926.x. Haemophilia. 2013. PMID: 23231016
Cited by
-
Social/economic costs and quality of life in patients with haemophilia in Europe.Eur J Health Econ. 2016 Apr;17 Suppl 1:53-65. doi: 10.1007/s10198-016-0785-2. Epub 2016 Apr 5. Eur J Health Econ. 2016. PMID: 27048374
-
Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan.Int J Hematol. 2019 Mar;109(3):336-345. doi: 10.1007/s12185-018-02574-x. Epub 2019 Jan 2. Int J Hematol. 2019. PMID: 30604312 Clinical Trial.
-
Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients.Haemophilia. 2022 Nov;28(6):e219-e227. doi: 10.1111/hae.14652. Epub 2022 Aug 22. Haemophilia. 2022. PMID: 35996199 Free PMC article. Clinical Trial.
-
Megakaryocyte- and megakaryocyte precursor-related gene therapies.Blood. 2016 Mar 10;127(10):1260-8. doi: 10.1182/blood-2015-07-607937. Epub 2016 Jan 19. Blood. 2016. PMID: 26787735 Free PMC article. Review.
-
Management of haemophilia A with inhibitors: A regional cross-talk.Haemophilia. 2022 Nov;28(6):950-961. doi: 10.1111/hae.14638. Epub 2022 Jul 22. Haemophilia. 2022. PMID: 35868021 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
